Joint Programming initiative on Antimicrobial Resistance (JPI AMR)
Antimicrobial Resistance - The Microbial Challenge - An Emerging Threat to Human Health
Antibiotic resistance is a global problem for all of us. Resistance leads to infections that cannot be easily treated with the current antibiotics. A global reduction of the resistance of harmful microbes to treatment such as antibiotics will lead to reduced health costs and saved lives. Research of the resistance in Europe is fragmented and few countries have specific programs dedicated to this field of research. To reach this goal, 23 countries have joined forces in the Joint Programme Initiative on Antimicrobial Resistance (JPIAMR) to coordinate the research, in order to allow greater impact and avoid duplication. Only by bringing together industry, public health bodies and academic bodies to share experience and resources across scientific disciplines will we be able to create long term reduction of antimicrobial resistance in Europe.
In January 2014 the first JPIAMR call was launched: "InnovaResistance: Innovative approaches to address antibacterial resistance". Read more.
On 12 May 2015, JPIAMR closed its 2nd call for proposals with 16 first stage proposals submitted. Proposals came from 10 different organisations in 9 countries; Argentina, Belgium, France, Germany, Italy, the Netherlands, Norway, Poland and the US. Read more.
The 3rd JPIAMR call, an ERA-NET Cofund Call on Transmission Dynamics with over 20 participating countries, opened in January 2016 and supported multidisciplinary research networks to conduct collaborative and complementary studies that will unravel the complex dynamics of selection and transmission of antimicrobial resistance to understand the mechanisms that contribute to the spread of resistance. Read more.
In February 2016, JPIAMR launched a rapid-action call for leading scientists in the field to establish international research networks: 4th Joint Call: Research Networking Programmes.
In January 2017, the 5th call was launched, on "Comparison of prevention, control and intervention strategies for AMR infections through multidisciplinary studies, including One Health approaches". Read more.
In January 2018 the 6th call has opened on "Innovations against antibiotic-resistant bacteria: new targets, compounds and tools - Fundamental, translational research, with the exception of clinical trials." Read more.
"Making beta-lactam antibiotics usable again". RIKILT microbiologist researcher Mariël Pikkemaat leads project in JPI Anti-Microbial Resistance (JPI AMR). The resistance to beta-lactam antibiotics is a major problem in health care. Often this problem is caused by bacteria that produce beta-lactamase enzymes, which degrade this group of antibiotics. This can be prevented by administering the antibiotic together with a substance which inhibits the enzyme from the bacterium. In this way existing beta-lactam antibiotics can be made usable again.